Skip to content
Review Open access

From bench to bedside: translational advances, therapeutic targets, and delivery strategies in diabetic retinopathy.

2026 · American journal of translational research · Vol 18 9, pp. 8254-8278 · 0 citations
Medicine

Abstract

Diabetic retinopathy (DR) is a leading cause of preventable blindness in adults of working age. Anti-vascular endothelial growth factor (anti-VEGF) therapy is the reference standard for diabetic macular edema (DME), yet in randomized cohorts, approximately 30-40% of DME eyes still show central macular thickening after six months of continuous treatment. In proliferative DR (PDR), the corresponding limitation is recurrence after treatment interruption rather than primary non-response, and these two patterns should not be conflated. This review examines translational research in DR across four domains. First, we review mechanistic work on the neurovascular unit, metabolic memory and its epigenetic substrate, the gut-retina axis, and human platforms including induced pluripotent stem cell (iPSC)-derived retinal organoids and clustered regularly interspaced short palindromic repeats (CRISPR) editing. Second, we discuss therapeutic targets beyond VEGF, including the nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome and related inflammatory pathways, neuroprotection, complement activation, the angiopoietin-2 (Ang2)/Tie2 axis, and non-coding RNA (ncRNA) networks. Third, in preclinical pharmacology, we regard delivery as the rate-limiting step and analyze in detail why lipid nanoparticle and N-acetylgalactosamine (GalNAc) conjugation strategies, which transformed hepatic RNA interference, have not translated to the retina, and what the terminated bevasiranib, PF-04523655, and iCo-007 programmes imply for trial design. Fourth, clinical translation, including cytokine biomarkers, artificial intelligence (AI)-based screening, combination regimens, and sustained-release implants. Evidence derived from age-related macular degeneration (AMD), including complement inhibition, stem cell transplantation, and photovoltaic implants, is evaluated separately, and its transferability to DR is assessed in light of differences in affected compartment, pathogenic driver, patient age, and expected treatment duration. We conclude that the principal obstacles in DR are no longer mechanistic but concern cell-type-specific delivery, early-phase trial design, and endpoint standardization, and we specify the evidence each candidate class should generate before clinical development proceeds.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.